Fracture protection in osteoporosis with risedronate

Hospital Medicine

Volumn 65, Issue 9, 2004, Pages 535-540

  Boonen, Steven ^a,b,c   Vanderschueren, Dirk ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b FUND FOR SCIENTIFIC RESEARCH   (Belgium)

^c Avenus Procter Gamble Pharmaceut   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; PLACEBO; RISEDRONIC ACID;

BONE MASS; BONE STRENGTH; CORTICOSTEROID INDUCED OSTEOPOROSIS; DENSITOMETRY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG INHIBITION; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FEMUR TROCHANTERIC FRACTURE; FRACTURE REDUCTION; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; INVOLUTIONAL BONE LOSS; LUMBAR SPINE; MEDICAL SOCIETY; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; RADIUS; REVIEW; TREATMENT PLANNING; WORLD HEALTH ORGANIZATION;

EID: 4644258357     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2004.65.9.15983     Document Type: Review

References (41)

1. Autier P, Haentjens P, Baillon J, Bentin, J, Grivegnee A, Closon M, Boonen S (2000) Costs induced by osteoporotic hip fractures: A prospective controlled study. Osteoporos Int 11: 373-80
2. Bone and Tooth Society of Great Britain, National Osteoporosis Society, Royal College of Physicians (2002) Glucocorticoid-induced Osteoporosis. Guidelines for Prevention and Treatment. Royal College of Physicians of London, London
3. Boonen S, Eastell R, Barton I, McClung M, Chesnut C (2003) Risedronate significantly reduces the risk of vertebral fractures in elderly menopausal women within 1 year. Calcif Tissue Int 72(4): 403, P277
4. Boonen S, Autier P, Barette M, Vanderchueren D, Lips P, Haentjens P (2004a) Functional outcome and quality of life following hip fracture in elderly women: A one-year prospective controlled study. Osteoporos Int 15: 87-94
5. Boonen S, Haentjens P, Vandenput L, Vanderchueren D (2004b) Preventing osteoporotic fractures with antiresorptive therapy: Implications of microarchitectural changes. J Intern Med 255: 1-12
6. Boonen S, McClung M, Eastell R, Fuleihan G, Barton I, Delmas P (2004c) Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women 80 years of age or older: Implications for the use of antiresorptive agents in the oldest old. J Am Geriatr Soc (in press)
7. Boonen S, Rizzoli R, Meunier P et al (2004d) The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: A consensus report. Osteoporos Int (in press)
8. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34(4): 736-46
9. Bose U, Burge RT, Worley D et al (2001) Current and future costs of osteoporotic fractures in the United Kingdom. Osteoporos Int 12(suppl 2): S7-8
10. British Medical Association and Royal Pharmaceutical Society of Great Britain (2003) British National Formulary. Number 46. British Medical Association and Royal Pharmaceutical Society of Great Britain, London http://www.bnf.org.uk/ (accessed 14 November 2003)
11. Brown JP, Kendler DL, McClung MR et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71: 103-11
12. Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103(2A): 12S-19S
13. Cummings SR, Melton III LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359: 1761-7
14. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281-9
15. Delmas P (2002) Treatment of postmenopausal osteoporosis. Lancet 359: 2018-26
16. Dufresne TE, Chmielewski PA, Manhart MD et al (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73(5): 423-32
17. Follin SL, Hansen LB (2003) Current approaches to the prevention and treatment of postmenopausal osteoporosis. Am J Health Syst Pharm 60: 883-901
18. Haentjens P, Autier P, Boonen S (2001) The economic cost of hip fractures among elderly women: A one-year prospective observational cohort study with matched-pair analysis. J Bone Joint Surg Am 83: 493-500
19. Harrington J, Ste-Msrie L, Brandi M et al (2004) Risedronate reduces the risk for nonvertebral fractures within 6 months in women with postmenopausal osteoporosis. Calcif Tiss Int 74: 129-35
20. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomised controlled trial. JAMA 282: 1344-52
21. Heaney RP, Zizic TM, Fogelman I et al (2002) Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 13: 501-5
22. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359: 1929-36
23. Lindsay R, Silverman SL, Cooper C et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285: 320-3
24. McClung MR, Bensen W, Bolognese MA et al (1997) Risedronate increases BMD at the hip, spine and radius in postmenopausal women with low bone mass [abstract]. J Bone Miner Res 12(Suppl 1): S169
25. McClung MR, Geusens P, Miller P et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333-40
26. National Institutes of Health (NIH) Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy (2001) Osteoporosis prevention, diagnosis and therapy. JAMA 285: 785-95
27. National Osteoporosis Society (2003) What is osteoporosis? www.nos.org.uk/osteo.asp (accessed 14 November 2003)
28. Nevitt MC, Ettinger B, Black DM et al (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Int Med 128: 793-800
29. Paschalis EP, Phipps R (2003) Three-years treatment with risedronate preserves bone quality. Poster presented at 30th European Symposium on Calcified Tissue P212. www.ectsoc.org/rome2003/posters5.htm (accessed 26 August 2004)
30. Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9(5): 461-8
31. Procter & Gamble Pharmaceuticals (2002) Actonel 35 mg Summary of Product Characteristics. Procter & Gamble Pharmaceuticals, Egham, Surrey
32. Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Osteoporosis: clinical guidelines for prevention and treatment. Update and pharmacological interventions and an algorithm for management. Royal College of Physicians, London www.rcplondon.ac.uk/pubs/wposteoupdate.htm (accessed 14 November 2003)
33. Roux C, Seemna E, Eastell R et al (2004) Risedronate reduces the risk of clinical vertebral fractures in 6 months. Curr Med Res Opin 20: 433-9
34. Seeman E (2002) Pathogenesis of bone fracture in women and men. Lancet 359: 1841-50
35. Sorensen OH, Crawford GM, Mulder H et al (2003a) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32: 120-6
36. Sorensen O, Goemaere S, Wenderoth D et al (2003b) Sustained effect of risedronate: a 7-year study in postmenopausal women. Poster 275. Presented at the 30th European Symposium on Calcified Tissue, Rome, 8-12 May http://www.ectsoc.org/rome2003/posters6.htm (accessed 14 November 2003)
37. Taggart H, Bolognese MA, Lindsay R et al (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77: 262-70
38. Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67: 277-85
39. Watts NB, Cline G, Kasibhatla C (2002) BMD increase accounts for only a fraction of the vertebral fracture reduction at 1 year: Results from the VERT and HIP trials of risedronate. Osteoporos Int 13(suppl 3): P54
40. Watts NB, Worley K (2003) An observational analysis of the nonvertebral efficacy of bisphosphonates: The Protocare Evaluation of Clinical Therapies (P.R.O.T.E.C.T.) Study. Osteoporos Int 14 (suppl 7): S77
41. Worley K, Doyle JJ, Sheer RL, Burge RT, Saadi H, Steinbuch M (2003) Incidence of gastrointestinal events among women treated with bisphosphonates for osteoporosis. Fourth European Symposium on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Osteoporos Int 14(suppl 7): S83